Clinical Trial Update: Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation [Phase 2]

View source ↗

Summary

Phase 2 study evaluating a combination of Itacitinib, Tacrolimus, and Sirolimus for prevention of graft-versus-host disease in patients with acute leukemia, mye…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome
• Myelofibrosis

Drugs mentioned

• Itacitinib (itacitinib)
• Sirolimus (Sirolimus)
• Tacrolimus (Tacrolimus)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Acute Leukemia, Hematologic and Lymphocytic Disorder | Phase 2 | Status: COMPLETED | Results posted: 2023-09-13